{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Objective Response Rate (ORR) is defined as the percentage of participants with a confirmed Best overall response of Complete Response (CR) or Partial Response (PR) by RECIST v1.1.\n\nComplete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\\\\\< 10 mm.\n\nPartial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.","groups":[{"description":"Part 2A were planned to evaluate BMS-986466 in combination with adagrasib in KRAS G12C-mutant (G12C inhibitor treatment-naïve) NSCLC participants.","id":"OG000","title":"Part 2A"},{"description":"Part 2B were planned to evaluate BMS-986466 in combination with adagrasib with or without cetuximab in KRAS G12C-mutant(G12C inhibitor treatment-naïve) CRC participants.","id":"OG001","title":"Part 2B"}],"populationDescription":"All treated population include all participants who received at least 1 dose of study intervention. Participants were not enrolled in Part 2, hence participants analyzed is 0. Prespecified to be collected for Part 2 only","reportingStatus":"POSTED","timeFrame":"From randomization untill disease progression or death, whichever occurs first (up to approximately 5 months)","title":"Part 2 Objective Response Rate (ORR) Assessed by Blinded Independent Central Review (BICR) as Per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1","type":"PRIMARY"}